Neurocrine Biosciences (NBIX) Leases (2019 - 2025)
Neurocrine Biosciences (NBIX) has disclosed Leases for 6 consecutive years, with $455.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases fell 10.6% year-over-year to $455.4 million, compared with a TTM value of $455.4 million through Dec 2025, down 10.6%, and an annual FY2025 reading of $455.4 million, down 10.6% over the prior year.
- Leases was $455.4 million for Q4 2025 at Neurocrine Biosciences, down from $468.9 million in the prior quarter.
- Across five years, Leases topped out at $509.4 million in Q4 2024 and bottomed at $80.8 million in Q3 2023.
- Average Leases over 4 years is $264.1 million, with a median of $257.3 million recorded in 2024.
- The sharpest move saw Leases soared 220.85% in 2024, then decreased 10.6% in 2025.
- Year by year, Leases stood at $97.9 million in 2021, then soared by 103.27% to $199.0 million in 2023, then soared by 155.98% to $509.4 million in 2024, then dropped by 10.6% to $455.4 million in 2025.
- Business Quant data shows Leases for NBIX at $455.4 million in Q4 2025, $468.9 million in Q3 2025, and $492.3 million in Q2 2025.